Congress Asset Management Co. MA Grows Stock Holdings in Option Care Health, Inc. (NASDAQ:OPCH)

Congress Asset Management Co. MA grew its holdings in shares of Option Care Health, Inc. (NASDAQ:OPCH) by 37.2% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 203,569 shares of the company’s stock after purchasing an additional 55,233 shares during the quarter. Congress Asset Management Co. MA owned approximately 0.12% of Option Care Health worth $6,858,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Vanguard Personalized Indexing Management LLC increased its stake in shares of Option Care Health by 16.2% during the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 10,000 shares of the company’s stock valued at $324,000 after acquiring an additional 1,392 shares during the last quarter. Rhumbline Advisers raised its stake in Option Care Health by 5.0% during the third quarter. Rhumbline Advisers now owns 555,194 shares of the company’s stock worth $17,961,000 after purchasing an additional 26,577 shares during the period. Envestnet Asset Management Inc. boosted its holdings in shares of Option Care Health by 278.5% in the 3rd quarter. Envestnet Asset Management Inc. now owns 108,391 shares of the company’s stock valued at $3,506,000 after purchasing an additional 79,751 shares during the last quarter. FMR LLC increased its holdings in shares of Option Care Health by 10.8% during the 3rd quarter. FMR LLC now owns 3,717,299 shares of the company’s stock worth $120,255,000 after buying an additional 362,828 shares during the last quarter. Finally, CI Investments Inc. raised its position in shares of Option Care Health by 109.2% in the 3rd quarter. CI Investments Inc. now owns 7,810 shares of the company’s stock worth $253,000 after buying an additional 4,076 shares during the period. Institutional investors and hedge funds own 98.05% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have commented on OPCH. Barrington Research restated an “outperform” rating and set a $38.00 price target on shares of Option Care Health in a research note on Wednesday, April 24th. Jefferies Financial Group increased their target price on shares of Option Care Health from $36.00 to $38.00 and gave the stock a “buy” rating in a research report on Monday, March 4th.

Option Care Health Price Performance

Shares of NASDAQ OPCH opened at $27.87 on Monday. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.77 and a quick ratio of 1.39. Option Care Health, Inc. has a 1-year low of $26.17 and a 1-year high of $35.74. The company has a market capitalization of $4.84 billion, a price-to-earnings ratio of 18.34, a PEG ratio of 1.36 and a beta of 1.31. The business has a 50-day moving average of $29.87 and a 200-day moving average of $31.41.

Option Care Health (NASDAQ:OPCH) last issued its quarterly earnings data on Tuesday, April 23rd. The company reported $0.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.22 by $0.04. The company had revenue of $1.15 billion during the quarter, compared to the consensus estimate of $1.10 billion. Option Care Health had a net margin of 6.15% and a return on equity of 18.92%. Option Care Health’s revenue for the quarter was up 12.8% on a year-over-year basis. During the same quarter last year, the company earned $0.21 earnings per share. On average, equities analysts anticipate that Option Care Health, Inc. will post 1.19 EPS for the current fiscal year.

Option Care Health Company Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.